Document Detail

Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure.
MedLine Citation:
PMID:  25176136     Owner:  NLM     Status:  Publisher    
Background An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, and a heart rate of 70 beats per minute or more. Methods We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, added to standard background therapy, in 19,102 patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more (including 12,049 patients with activity-limiting angina [class ≥II on the Canadian Cardiovascular Society scale, which ranges from I to IV, with higher classes indicating greater limitations on physical activity owing to angina]). We randomly assigned patients to placebo or ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. The primary end point was a composite of death from cardiovascular causes or nonfatal myocardial infarction. Results At 3 months, the mean (±SD) heart rate of the patients was 60.7±9.0 beats per minute in the ivabradine group versus 70.6±10.1 beats per minute in the placebo group. After a median follow-up of 27.8 months, there was no significant difference between the ivabradine group and the placebo group in the incidence of the primary end point (6.8% and 6.4%, respectively; hazard ratio, 1.08; 95% confidence interval, 0.96 to 1.20; P=0.20), nor were there significant differences in the incidences of death from cardiovascular causes and nonfatal myocardial infarction. Ivabradine was associated with an increase in the incidence of the primary end point among patients with activity-limiting angina but not among those without activity-limiting angina (P=0.02 for interaction). The incidence of bradycardia was higher with ivabradine than with placebo (18.0% vs. 2.3%, P<0.001). Conclusions Among patients who had stable coronary artery disease without clinical heart failure, the addition of ivabradine to standard background therapy to reduce the heart rate did not improve outcomes. (Funded by Servier; SIGNIFY Current Controlled Trials number, ISRCTN61576291 .).
Kim Fox; Ian Ford; Philippe Gabriel Steg; Jean-Claude Tardif; Michal Tendera; Roberto Ferrari;
Related Documents :
3280846 - Application of positron emission tomography in the heart. council on scientific affairs...
25186106 - Uricaemia and left ventricular mass in hypertensive patients.
22404456 - Delineation of the etiology of a mass-like echo density in the left ventricle using thr...
19868566 - The influence of thyroid products on the production of myocardial necrosis.
15866246 - How should patients with unstable angina and non-st-segment elevation myocardial infarc...
22717376 - The functional effect of soybean extract and isolated isoflavone on myocardial infarcti...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-31
Journal Detail:
Title:  The New England journal of medicine     Volume:  -     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-9-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lactate retards development of erythrocytic stages of the human malaria parasite Plasmodium falcipar...
Next Document:  The Challenges with Chronic Angina.